A Diversified Portfolio
00
Compounds
on the market via our partners.
000
MA
obtained in Europe
00
Products
in development for market launch
In each of our areas of expertise, we seek to offer our partners appropriate therapeutic solutions. Our aim is to meet patients' real needs.
We Offer Solutions in a Number of Therapeutic Areas
Cardiology
Pain
Gastroenterology
Neurology
Infectiology
Anaesthesia and Intensive Care
Why Choose Generic Drugs?
Our desire to develop generic medicines is a duty to protect and perpetuate our public health system. In addition to the obvious fact that they are medicines and subject to the same rules and requirements as reference products, their development allowing healthcare economies to access these medicines in a sustainable and economic way will help overcome the major economic and public health challenges. Our generic medicines comply with the principles of safety, efficacy, quality and cost.
Why Choose Biosimilar Medicines?
Biosimilar medicines are clinically equivalent in terms of safety, efficacy and quality to reference biologics. They therefore offer a major leverage effect for strengthening our image, adding value to our organisation and making access to these medications for our healthcare system more financially viable by reducing the cost of acquisition in the treatment pathway.
Our Health Commitment
Since the launch of our business, we have attached great importance to the rigorous selection of our partners, assessing their production capacity, their vertical integration strategy and the diversity of their portfolio. Our aim is to offer our partners and healthcare professionals medicines that meet their quality, supply schedule and cost requirements. Our priority is to diversify our product portfolio to cover several therapeutic areas. Our approach is based on two key challenges: - guaranteeing a seamless supply process - making launch forecasts more reliable. Our goal is to minimise pressure on stocks while ensuring excellent value for money.